# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Peter Grom maintains Colgate-Palmolive (NYSE:CL) with a Buy and raises the price target from $119 to $122.
An initiative seeking to enable easier unionization in the cannabis industry in Oregon got the green light from the secretary o...
Cannabis producer and the operator of Sunnyside dispensaries Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) released on T...
TD Cowen analyst Robert Moskow maintains Colgate-Palmolive (NYSE:CL) with a Buy and raises the price target from $110 to $115.
Bernstein analyst Callum Elliott maintains Colgate-Palmolive (NYSE:CL) with a Market Perform and raises the price target fro...
Originally published at VolumeLeaders What to expect for July 29- August 02, 2024
Deutsche Bank analyst Steve Powers maintains Colgate-Palmolive (NYSE:CL) with a Buy and raises the price target from $104 to...
Morgan Stanley analyst Dara Mohsenian maintains Colgate-Palmolive (NYSE:CL) with a Overweight and raises the price target fr...